HER-2-neu peptide vaccine

Known as: HER-2, HER-2/neu Helper-Peptide Vaccine, HER-2/neu peptide vaccine 
A cancer vaccine comprised of peptides derived from the extracellular domain of the tumor-associated antigen Her-2/neu with potential antineoplastic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2017
05010015019892017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
PURPOSE To determine whether breast cancer subtype is associated with outcome after breast-conserving therapy (BCT) consisting of… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Triple-negative breast cancer (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) is a… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The majority of breast cancer patients who achieve an initial therapeutic response to the human epidermal growth factor receptor… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND HER-2/neu gene amplification has predictive value in breast cancer patients responding to trastuzumab. We wanted to… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
RNA interference (RNAi) represents a powerful, naturally occurring biological strategy for inhibition of gene expression. It is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND AIB1 (SRC-3) is an estrogen receptor (ER) coactivator that, when overexpressed in cultured cells, can reduce the… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Women with HER-2 overexpressing metastatic breast carcinoma benefit from trastuzumab-based therapy, but trastuzumab… (More)
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected based on the presence of HLA-A2.1… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?